Johann Hari: They’re Lying To You About The Side Effects Of Ozempic!
Author Johann Hari describes a year on semaglutide and walks through the benefits and risks he found while researching his book on weight loss drugs.
With Johann Hari, Steven
Key moments
Tap a moment to play the video from there.
- 6:37The pen, dose and priceHari describes the weekly injection pen and says it costs about 250 pounds a month in Britain and 800 to 1,200 dollars a month in the US. He recalls losing nearly all his appetite from the first week.
- 9:51How GLP-1 drugs workHari says the drug copies the satiety hormone GLP-1 but lasts a week instead of minutes. He adds that leading neuroscientists now think its main effect is on the brain.
- 16:03Three theories about the brainHari sets out three views: the drug dampens reward, resets food preferences, or turns up the satiety system. He notes scientists disagree and that a suicide warning was required by the FDA.
- 22:53Cheesecake Park and satietyHari describes a preclinical experiment by Paul Kenny in which a junk food diet wrecked the animals' ability to stop eating. He argues the drugs restore the satiety signal that modern food erodes.
- 42:20Bariatric surgery as a comparisonHari uses bariatric surgery as the closest precedent. He cites better physical outcomes alongside higher rates of psychiatric treatment, suicide and addiction transfer.
- 1:05:44Eating disorders and easy accessHari says he is very worried about young women with eating disorders getting the drugs online. He supports in-person prescribing by doctors trained to spot eating disorders.
- 1:10:51Thyroid, pancreatitis and Ozempic faceHari goes through a French study on thyroid cancer, a study on pancreatitis, and the cosmetic effect known as Ozempic face. He notes the thyroid finding is disputed.
- 1:23:00Past diet drugs and unknownsHari recounts dinitrophenol, amphetamines and fen-phen as warnings from history. He says a scientist named unknown unknowns as the biggest risk of the new drugs.
- 2:05:37Addiction researchHari describes preclinical studies where these drugs cut alcohol, heroin, fentanyl and cocaine use by roughly 50 to 60%. He says early human studies are small and mixed.
- 2:17:07Who should and should not take themHari says people who are not overweight should not take the drugs. He says he is fairly confident recommending them above a BMI of 35 and sees a judgment call between 27 and 35.
What the video says
Johann Hari, author of Magic Pill, tells host Steven about a year of taking semaglutide (sold as Ozempic and Wegovy) and the interviews he did with the scientists behind these drugs. The conversation also covers diet history, food environments and celebrity weight loss, but most of it concerns what the drugs do and what could go wrong.
Hari explains that semaglutide copies the gut hormone GLP-1 and stays in the body for a week, and he says he felt about 80% less hungry. He reports losing three stone and moving from 33% to 22% body fat. He says researchers now think the drug acts mainly on the brain, and he lays out three competing theories: it dampens reward, it resets food preferences, or it strengthens the sense of fullness. He also discusses preclinical studies in which the drugs reduced alcohol and drug use, and says early human results are small and mixed.
Hari lists what he calls 12 significant risks and covers several in detail. He cites a French study reporting a 50 to 75% higher thyroid cancer risk in diabetics, which he says some scientists and the European Medicines Agency dispute. He cites a University of British Columbia study putting pancreatitis risk at nine times higher, though still rare. He also covers muscle loss, a possible link to suicidal feelings, lost comfort eating, eating disorders, regaining about 70% of weight within a year of stopping, and unknown long-term effects. He compares all this with past diet drugs, including fen-phen.
Hari stresses that the evidence is contested and that he stays conflicted. He argues the drugs are an artificial fix for a food environment he blames on the food industry, and he points to Japan's school meals as a different model. He says people who are not overweight should not take them, and that he would recommend them to people with a BMI above 35 who have no thyroid cancer in the family and are not trying to get pregnant. The final stretch covers Hollywood weight loss, shortages affecting diabetics, and exercise.
“We do know the long-term risks of obesity, and they are horrific.”
What this video doesn’t settle
- It is largely one person's year of use plus his interviews, with no control group, so his weight and appetite results do not show what to expect for anyone else.
- Hari says scientists disagree on whether the drugs dampen reward or raise satiety, so the video does not establish how they act in the brain.
- The thyroid cancer and suicidality concerns are presented as disputed, and the video does not settle whether either risk is real.
Questions this video answers
What are the main risks of Ozempic according to Johann Hari?
Hari says he found 12 significant risks. He discusses a reported 50 to 75% higher thyroid cancer risk in a French diabetic study, a nine times higher pancreatitis risk, muscle loss, possible suicidal feelings, eating disorders and unknown long-term effects. He says several of these are disputed or rare.
Do people regain weight after stopping Ozempic?
Hari says that within a year of stopping, people regain about 70% of the weight they lost, and that this is not true for everyone. He says he would expect to regain a lot of weight himself.
How does semaglutide work according to this video?
Hari says it is an artificial copy of GLP-1 that stays in the body for a week and signals fullness. He says the leading view now is that it acts mainly on the brain, and he notes scientists disagree on how.
Can Ozempic help with addiction?
Hari says preclinical studies showed large drops in alcohol, heroin, fentanyl and cocaine use, and some people report fewer compulsive behaviours. He says early human studies are small and mixed and the idea is still speculative.
Who does Johann Hari say should avoid these drugs?
Hari says people who are not overweight or obese should not take them. He also advises against them for people with thyroid cancer in the family and for those worried about muscle mass.
Video by The Diary Of A CEO on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
